FEB 22, 2016 2:42 PM PST

New T-Cell Leukemia Treatment Target Identified

WRITTEN BY: Kara Marker
Around 15 to 20 percent of children with acute lymphoblastic leukemia (ALL) have cancerous cells derived from T lymphocytes (immune cells), as opposed to B lymphocytes (American Cancer Society). Currently, over half of adults and 20 percent of children with T-cell ALL end up dying. New research from Boston University Medical College (BUMC) researchers offers a potential solution for lowering those fatality rates; their new study published in Leukemia  identifies a specific enzyme that cancer cells rely on for survival.
 

 
During the tricarboxylic acid (TCA) cycle, a key step in the process of cellular aerobic respiration, cells transform pyruvate received from glycolysis into energy through oxidation of acetyl-CoA (Georgia State University). The new BUMC study identified a key enzyme involved in this process called DLST, which cancer cells require for adequate growth and survival. They discovered the cancer cell dependence on DLST by performing genetic screenings on a zebrafish model of disease, looking for specific mutations that suppress tumor development.
 
Indeed, inhibiting DLST in the zebra fish model “significantly delayed tumor onset in zebrafish without detectable effects on fish development” (Leukemia 2016). They also successfully tested DLST enzyme activity inhibition with human T-cell leukemia cells.
 
A new prospect for T-cell ALL treatment utilizing DLST inhibition is promising, especially because current treatments for this cancer are highly toxic even if they are successful in healing the patient. This finding is also significant because prior to this research, scientists did not believe that cancer cells relied on the TCA cycle for survival.
 
“Our new findings provide solid evidence that these cancer cells depend on the TCA cycle for their survival," explained corresponding author Hui Feng, MD, PhD. "Additionally we demonstrated the importance of DLST in T-cell leukemia development, and have identified a targetable enzyme for T-cell leukemia treatment.”
 

Source: BUMC
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 03, 2021
Clinical & Molecular DX
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
FEB 03, 2021
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
Rheumatoid arthritis, or RA, is a painful and debilitating autoimmune disorder of the joints, particularly those of the ...
FEB 10, 2021
Drug Discovery & Development
Black Men Respond Best to Immunotherapy for Prostate Cancer
FEB 10, 2021
Black Men Respond Best to Immunotherapy for Prostate Cancer
Researchers from Northwestern University have found that Black men and men of African ancestry respond better than men f ...
MAR 18, 2021
Immunology
COVID Cytokine Storm Chasers Look Inside the Lungs
MAR 18, 2021
COVID Cytokine Storm Chasers Look Inside the Lungs
Immunologists have revealed one of the underlying mechanisms behind COVID’s life-threatening cytokine storms. By s ...
APR 03, 2021
Cancer
New factor plays a key role in immune response
APR 03, 2021
New factor plays a key role in immune response
In a study published recently in Science Immunology, WEHI’s Professor Stephen Nutt, Dr. Michael Chopin, and Mr. Sh ...
APR 21, 2021
Immunology
Human T Cells Can't Recognize COVID Mutants
APR 21, 2021
Human T Cells Can't Recognize COVID Mutants
Genetic variants of the SARS-CoV-2 virus have emerged and tightened their grip on global communities as the pandemic rag ...
JUN 08, 2021
Immunology
Is the Pfizer-BioNtech Vaccine Variant-Resistant?
JUN 08, 2021
Is the Pfizer-BioNtech Vaccine Variant-Resistant?
Genetic variants of SARS-CoV-2 have emerged over the course of the pandemic, threatening public health efforts to limit ...
Loading Comments...